Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells

Waseem Qasim

Blood (2023) 141 (8): 835–845.

https://doi.org/10.1182/blood.2022016204

Published: 2023

Journal Articles

Tvt CAR7: Phase 1 Clinical Trial of Base-Edited "Universal” CAR7 T Cells for Paediatric Relapsed/Refractory T-ALL

Blood (2022) 140 (Supplement 1): 4579–4580.

https://doi.org/10.1182/blood-2022-169114

Published: 2022

Journal Articles

Single and Combinational Multiplex Base-Edited 'Universal' CAR T Cells in a Humanised Model of Primary CD7+CD33+ AML

Arnold Kloos, Christos Georgiadis, Annie Etuk, Soragia Athina Gkazi, Farhatullah Syed, Toni Braybrook, Hong Zhan, Renuka Kadirkamanathan, Nadine Kattre, Kerstin Görlich, Thomas Fangmann, Axel Schambach, Martin G. Sauer, Michael Heuser, Waseem Qasim

Blood (2022) 140 (Supplement 1): 7425–7426.

https://doi.org/10.1182/blood-2022-168719

Published: 2022

Journal Articles

TT52CAR19: Phase 1 Trial of CRISPR/Cas9 Edited Allogeneic CAR19 T Cells for Paediatric Relapsed/Refractory B-ALL

Giorgio Ottaviano, Christos Georgiadis, Farhatullah Syed, Soragia Athina Gkazi, Hong Zhan, Annie Etuk, Jan Chu, Danielle Pinner, Sarah Inglott, Kimberly Gilmour, Stuart Adams, Susanne Kricke, Natalia Izotova, Dariusz Ladon, Agnieszka Kubat, Paul Veys, Ajay Vora, Kanchan Rao, Waseem Qasim

Blood (2021) 138 (Supplement 1): 4838.

https://doi.org/10.1182/blood-2021-152426

Published: 2021

Journal Articles

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-137768

Published: 2020

Journal Articles

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 1367.

https://doi.org/10.1182/blood-2019-128044

Published: 2019

Journal Articles

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

Blood (2019) 134 (Supplement_1): 776.

https://doi.org/10.1182/blood-2019-129640

Published: 2019

Journal Articles

Highly Efficient Multiplexed Base Editing with Minimized Off-Targets for the Development of Universal CAR-T Cells to Treat Pediatric T-ALL

Jason M Gehrke, PhD, Aaron Edwards, MS, Ryan C. Murray, MS, Amy Shaw, MS, Yeh-Chuin Poh, PhD, Sarah Smith, Yi Yu, PhD, Nicole M. Gaudelli, PhD, Waseem Qasim, MBBS, PhD, Giuseppe Ciaramella, PhD, B.Sc.

Blood (2019) 134 (Supplement_1): 5127.

https://doi.org/10.1182/blood-2019-130562

Published: 2019

Journal Articles

Universal' Fratricide-Resistant CAR T Cells Against T Cell Leukemia Generated By Coupled & Uncoupled Deamination Mediated Base Editing

Christos Georgiadis, PhD, Jane Rasaiyaah, PhD, Soragia Athina Gkazi, PhD, Roland Preece, Annie Etuk, PhD, Abraham Christi, Waseem Qasim, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3219.

https://doi.org/10.1182/blood-2019-130057

Published: 2019

Journal Articles

Administration of BPX-501 Cells Following Αβ T and B-Cell-Depleted HLA-Haploidentical HSCT (haplo-HSCT) in Children with Malignant or Non-Malignant Disorders

Mattia Algeri, MD, Pietro Merli, MD, Waseem Qasim, MD PhD, Mary Slatter, MD, Melissa Kuhn, PharmD, Franco Locatelli

Blood (2018) 132 (Supplement 1): 2171.

https://doi.org/10.1182/blood-2018-99-119635

Published: 2018

Journal Articles

Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood (2018) 132 (Supplement 1): 896.

https://doi.org/10.1182/blood-2018-99-111356

Published: 2018

Journal Articles

Administration of BPX-501 Cells Following Aβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias

Franco Locatelli, Annalisa Ruggeri, MD PhD, Pietro Merli, MD, Swati Naik, MBBS, Rajni Agarwal, MD, Victor Aquino, MD, David A. Jacobsohn, MD, Waseem Qasim, MD PhD, Eneida R. Nemecek, MD, Lakshmanan Krishnamurti, MD, Deepa Manwani, MD, Melissa Kuhn, PharmD, Neena Kapoor

Blood (2018) 132 (Supplement 1): 307.

https://doi.org/10.1182/blood-2018-99-119481

Published: 2018

Journal Articles

Automated Manufacture of CAR19 Donor Lymphocytes Incorporated into an Escalated Dose DLI Protocol: Preliminary Results from the CARD Study

Blood (2017) 130 (Supplement 1): 1993.

https://doi.org/10.1182/blood.V130.Suppl_1.1993.1993

Published: 2017

Journal Articles

Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product in a First-in-Human Trial (PALL) in Pediatric Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 1271.

https://doi.org/10.1182/blood.V130.Suppl_1.1271.1271

Published: 2017

Journal Articles

Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG /NEMO mutations

Blood (2017) 130 (12): 1456–1467.

https://doi.org/10.1182/blood-2017-03-771600

Published: 2017

Includes: Supplemental data

Journal Articles

Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations

Blood (2017) 129 (11): 1458–1468.

https://doi.org/10.1182/blood-2016-10-745174

Published: 2017

Journal Articles

Outcome of Children with Primary Immune-Deficiencies (PIDs) Enrolled in a Phase I-II Trial Based on the Infusion of BPX-501 Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9, iC9) after T-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (haplo-HSCT)

Neena Kapoor, MD, Alice Bertaina, MD PhD, Pietro Merli, MD, Swati Naik, MD, Waseem Qasim, MBBS PhD, Mary Slatter, MD, Reem Elfeky, MD, Barbarella Lucarelli, MD, Monika Smogorzewska, PhD, Giuseppina Li Pira, PhD, Valentina Bertaina, PhD, Annemarie Moseley, MD PhD, Franco Locatelli, MD

Blood (2016) 128 (22): 72.

https://doi.org/10.1182/blood.V128.22.72.72

Published: 2016

Journal Articles

A Novel Second Generation CD19 CAR for Therapy of High Risk/Relapsed Paediatric CD19 + Acute Lymphoblastic Leukaemia and Other Haematological Malignancies: Preliminary Results from the Carpall Study

Sara Ghorashian, MD PhD FRCPath, Anne Marijn Kramer, MD, Sarah Jayne Albon, BSc, MSc, Catherine Irving, BSc, Lucas Chan, PhD, Fernanda Castro, PhD, Bilyana Popova, Kim Champion, PhD, Gary Wright, Hong Zhan, PhD, Waseem Qasim, MBBS PhD, Robert Wynn, Rachael Hough, MD BMBS, FRCP, FRCPath, Farzin Farzaneh, Martin A Pule, MD PhD, Persis J Amrolia, Professor

Blood (2016) 128 (22): 4026.

https://doi.org/10.1182/blood.V128.22.4026.4026

Published: 2016

Journal Articles

Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells

Prashant Hiwarkar, Waseem Qasim, Ida Ricciardelli, Kimberly Gilmour, Sergio Quezada, Aurore Saudemont, Persis Amrolia, Paul Veys

Blood (2015) 126 (26): 2882–2891.

https://doi.org/10.1182/blood-2015-06-654780

Published: 2015

Includes: Supplemental data

Journal Articles

Automated Lentiviral Transduction of T Cells with Cars Using the Clinimacs Prodigy

Ulrike Mock*, PhD, Lauren Nickolay*, PhD, Gordon Weng-Kit Cheung, Hong Zhan, PhD, Karl Peggs, MBBChir, MRCP, FRCPath, Ian CD Johnston, PhD, Andrew Kaiser, PhD, Martin Pule, PhD, Adrian Thrasher, MD PhD, Waseem Qasim, MBBS PhD

Blood (2015) 126 (23): 2043.

https://doi.org/10.1182/blood.V126.23.2043.2043

Published: 2015

NARROW

Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells

Tvt CAR7: Phase 1 Clinical Trial of Base-Edited "Universal” CAR7 T Cells for Paediatric Relapsed/Refractory T-ALL

Single and Combinational Multiplex Base-Edited 'Universal' CAR T Cells in a Humanised Model of Primary CD7+CD33+ AML

TT52CAR19: Phase 1 Trial of CRISPR/Cas9 Edited Allogeneic CAR19 T Cells for Paediatric Relapsed/Refractory B-ALL

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

Highly Efficient Multiplexed Base Editing with Minimized Off-Targets for the Development of Universal CAR-T Cells to Treat Pediatric T-ALL

Universal' Fratricide-Resistant CAR T Cells Against T Cell Leukemia Generated By Coupled & Uncoupled Deamination Mediated Base Editing

Administration of BPX-501 Cells Following Αβ T and B-Cell-Depleted HLA-Haploidentical HSCT (haplo-HSCT) in Children with Malignant or Non-Malignant Disorders

Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Administration of BPX-501 Cells Following Aβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias

Automated Manufacture of CAR19 Donor Lymphocytes Incorporated into an Escalated Dose DLI Protocol: Preliminary Results from the CARD Study

Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product in a First-in-Human Trial (PALL) in Pediatric Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG /NEMO mutations

Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations

A Novel Second Generation CD19 CAR for Therapy of High Risk/Relapsed Paediatric CD19 + Acute Lymphoblastic Leukaemia and Other Haematological Malignancies: Preliminary Results from the Carpall Study

Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells

Automated Lentiviral Transduction of T Cells with Cars Using the Clinimacs Prodigy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only